AcelRx Pharmaceuticals, Inc. (ACRX) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) from a buy rating to a hold rating in a report issued on Thursday, May 11th.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

Several other research firms also recently weighed in on ACRX. Cowen and Company restated a hold rating on shares of AcelRx Pharmaceuticals in a research report on Monday, March 6th. Roth Capital set a $15.00 price target on shares of AcelRx Pharmaceuticals and gave the stock a buy rating in a research report on Monday, March 6th. Stifel Nicolaus reduced their price target on shares of AcelRx Pharmaceuticals from $15.00 to $14.00 and set a hold rating for the company in a research report on Tuesday, March 14th. Finally, Royal Bank of Canada restated an outperform rating and set a $6.00 price target on shares of AcelRx Pharmaceuticals in a research report on Friday, March 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $8.67.

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 2.40 on Thursday. The firm’s 50-day moving average price is $2.52 and its 200-day moving average price is $2.80. AcelRx Pharmaceuticals has a 12-month low of $1.95 and a 12-month high of $4.08. The company’s market capitalization is $108.91 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.06. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. The firm had revenue of $3.11 million for the quarter, compared to analysts’ expectations of $2.36 million. On average, analysts expect that AcelRx Pharmaceuticals will post ($1.10) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/06/17/acelrx-pharmaceuticals-inc-acrx-downgraded-by-zacks-investment-research-to-hold-updated-updated-updated.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in AcelRx Pharmaceuticals by 196.3% in the third quarter. Wells Fargo & Company MN now owns 28,403 shares of the specialty pharmaceutical company’s stock worth $111,000 after buying an additional 18,818 shares during the last quarter. ING Groep NV increased its stake in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares during the last quarter. Acadian Asset Management LLC increased its stake in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares during the last quarter. Teachers Advisors LLC increased its stake in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares during the last quarter. Finally, Oxford Asset Management increased its stake in AcelRx Pharmaceuticals by 48.7% in the fourth quarter. Oxford Asset Management now owns 103,420 shares of the specialty pharmaceutical company’s stock worth $269,000 after buying an additional 33,866 shares during the last quarter. Institutional investors own 30.28% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about AcelRx Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AcelRx Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit